<DOC>
	<DOCNO>NCT00084942</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine capecitabine , work different way stop tumor cell divide stop grow die . Combining one chemotherapy drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine gemcitabine capecitabine treat patient advanced and/or inoperable cholangiocarcinoma carcinoma ( cancer ) gallbladder .</brief_summary>
	<brief_title>Gemcitabine Capecitabine Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma Carcinoma Gallbladder</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient advance and/or inoperable cholangiocarcinoma carcinoma gallbladder treat gemcitabine capecitabine . Secondary - Determine time disease progression overall survival patient treat regimen . - Determine quality life patient treat regimen . OUTLINE : This open-label study . Patients receive gemcitabine IV 30 minute day 1 8 oral capecitabine twice daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Quality life assess baseline week 3 , 6 , 9 , 12 . Patients follow monthly . PROJECTED ACCRUAL : A total 9-17 patient accrue study within 1.5 year .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm cholangiocarcinoma carcinoma gallbladder Advanced and/or inoperable disease Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 2 month Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin &lt; 3 mg/dL Renal Creatinine ≤ 1.6 mg/dL Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction attribute compound similar chemical biological composition study drug No ongoing active infection No psychiatric illness social situation would preclude study compliance No concurrent uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 4 week since prior chemotherapy recover No 1 prior chemoembolization OR chemoradiotherapy regimen locally advance biliary tract cancer No prior chemotherapy ( except adjuvant therapy ) Endocrine therapy Not specify Radiotherapy See Chemotherapy More 4 week since prior radiotherapy recover Surgery Not specify Other No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>cholangiocarcinoma extrahepatic bile duct</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
</DOC>